Home > Healthcare > Pharmaceuticals > Finished Drug Form > Heparin Market

Heparin Market Size

  • Report ID: GMI4837
  • Published Date: Feb 2022
  • Report Format: PDF

Heparin Market Size

Heparin Market size was worth over USD 4.8 billion in 2022. Driven by the high prevalence rate of chronic disorders globally, the industry could grow at over 2.5% CAGR from 2023 to 2032.

 

Surging occurrence of chronic disorders such as coronary artery disease, thromboembolism, and others that result in blood clot formation has increased the need for heparin. As per CDC, in 2021, 2 in every 10 mortalities from coronary artery disease occurred in adults below the age of 65 years. Moreover, the growing demand for anticoagulants in hemodialysis, open heart surgery, and other interventional procedures will create ample opportunities for industry expansion.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

In 2022, the heparin industry size was valued at more than USD 4.8 billion in 2022 and will grow at over 2.5% CAGR from 2023 to 2032, attributed to the growing occurrence of chronic disorders globally.

The low molecular weight heparin industry was worth over USD 4.2 billion in 2022, owing to the rising prevalence of deep vein thrombosis.

Europe heparin market held more than 58.5% market share in 2022, on account of the surging prevalence of venous thromboembolism, ischemic heart disease, and other cardiovascular diseases that lead to blood clot formation in the region.

Major heparin industry players include Amphastar, Leo Pharma, Rovi, Sanofi, Changzhou Qianhong Biopharma, Pfizer, Shenzhen Hepalink, and Nanjing King-Friend Biochemical Pharmaceutical, among others.

Heparin Market Scope

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 287
  • Countries covered: 23
  • Pages: 160
 Download Free Sample